MBRX
Price:
$2.64
Market Cap:
$14.09M
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is de...[Read more]
Industry
Biotechnology
IPO Date
2016-06-02
Stock Exchange
NASDAQ
Ticker
MBRX
According to Moleculin Biotech, Inc.’s latest financial reports and current stock price. The company's current ROE is 3.11%. This represents a change of 5.56% compared to the average of 55.00% of the last 4 quarters.
The mean historical ROE of Moleculin Biotech, Inc. over the last ten years is -112.61%. The current 3.11% ROE has changed -2865.45% with respect to the historical average. Over the past ten years (40 quarters), MBRX's ROE was at its highest in in the June 2025 quarter at 106.63%. The ROE was at its lowest in in the March 2025 quarter at -15323.81%.
Average
-112.61%
Median
-84.01%
Minimum
-363.99%
Maximum
-20.12%
Discovering the peaks and valleys of Moleculin Biotech, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 218.80%
Maximum Annual ROE = -20.12%
Minimum Annual Increase = -126.12%
Minimum Annual ROE = -363.99%
| Year | ROE | Change |
|---|---|---|
| 2025 | -223.64% | -38.56% |
| 2024 | -363.99% | 218.80% |
| 2023 | -114.18% | 105.30% |
| 2022 | -55.61% | 176.40% |
| 2021 | -20.12% | -79.26% |
| 2020 | -97.01% | 14.40% |
| 2019 | -84.81% | 1.91% |
| 2018 | -83.21% | 45.27% |
| 2017 | -57.28% | 118.25% |
| 2016 | -26.25% | -126.12% |
The current ROE of Moleculin Biotech, Inc. (MBRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-233.94%
5-year avg
-155.51%
10-year avg
-112.61%
Moleculin Biotech, Inc.’s ROE is less than Apollomics, Inc. (288.40%), greater than Athira Pharma, Inc. (-381.01%), greater than SeaStar Medical Holding Corporation (-146.29%), less than Adaptimmune Therapeutics plc (472.78%), less than Lunai Bioworks Inc. (892.52%), greater than Citius Pharmaceuticals, Inc. (-67.42%), greater than Tharimmune, Inc. (-36.93%), greater than Ainos, Inc. (-160.55%), greater than BioLineRx Ltd. (-47.76%), greater than Leap Therapeutics, Inc. (-46.86%),
| Company | ROE | Market cap |
|---|---|---|
| 288.40% | $15.78M | |
| -381.01% | $26.62M | |
| -146.29% | $8.46M | |
| 472.78% | $75.16M | |
| 892.52% | $10.93M | |
| -67.42% | $6.03M | |
| -36.93% | $139.94M | |
| -160.55% | $8.65M | |
| -47.76% | $14.66M | |
| -46.86% | $31.86M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Moleculin Biotech, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Moleculin Biotech, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Moleculin Biotech, Inc.'s ROE?
How is the ROE calculated for Moleculin Biotech, Inc. (MBRX)?
What is the highest ROE for Moleculin Biotech, Inc. (MBRX)?
What is the 3-year average ROE for Moleculin Biotech, Inc. (MBRX)?
What is the 5-year average ROE for Moleculin Biotech, Inc. (MBRX)?
How does the current ROE for Moleculin Biotech, Inc. (MBRX) compare to its historical average?